|
|
|
Market Research Report
Epigenetics: Current and future applications that are driving novel drug discovery
|
Epigenetics: Current and future applications that are driving novel drug discovery published by Espicom Business Intelligence in August, 2010. This report consists of Pages: 80 and the price starts from US $ 1215.
Abstract
Summary
This new 75+ page, August 2010 report provides a complete briefing on the emerging importance of epigenetic research in drug and diagnostic development.
Category: Pharmaceuticals, Healthcare, Epigenetics
META Description
Epigenetics is an active and exciting area of research that is being driven by
the massive amounts of new information being generated by currently available
research tools, the potential for effective new therapies in areas of unmet
medical need and new diagnostic, screening or pharmacoepigenomic tests.
Significant investment is being made into basic research and will enable
standardised, whole epigenome maps that will be freely available for
additional research and analysis. This research will develop our understanding
of the interplay between different epigenetic mechanisms, and has the
potential to uncover new drug targets.
Commercially available products - current and near term
The development of new drugs and diagnostics based on our understanding of
epigenetic mechanisms and the ways in which they cause changes in gene
expression, is an area of research which has produced commercial products.
Whilst four drugs have already been marketed in this area, these represent the
tip of the iceberg. Scientists have now identified large numbers of individual
enzymes responsible for making specific alterations to histones and these are
the focus of drug discovery efforts. miRNA is also a growing field in terms of
both therapeutic and diagnostic development.
In addition to the four currently marketed drugs for epigenetic targets, more
than six additional drugs will reach the marketplace over the next decade.
These first generation products will be replaced in the longer-term by more
selective inhibitors of a wide range of novel epigenetic targets such as
histone methylases and demethylases, histone acetylases, and readers
(bromodomains and chromodomains).
Broadening the therapeutic horizon
Current pan- and class-selective histone deacetylase inhibitors will be
improved upon by the next generation of selective inhibitors. These offer
perhaps the greatest potential as they may be applicable outside the oncology
arena where the burden of toxicity must be low. The development of this
generation of targeted compounds will be undertaken alongside companion
diagnostic tests, helping to generate the best outcomes for individual
patients in the future.
Epigenetic Biomarkers
Over the next five years a number of new diagnostic tests will enter the
market based on the identification of epigenetic biomarkers. These tests will
focus on cancer and will progress from tissue or fine needle aspirate-based
diagnostic tests, to far less invasive bodily fluid (blood, sputum, urine)
based screening. Prognostic markers that will guide treatment decisions are
also on the radar. Further into the future these tests will broaden into
therapeutic areas other than cancer.
With this report you can...
Understand the current thinking in respect to epigenetic mechanisms: DNA
methylation, Chromatin remodelling/histone modifications and Non-coding RNA
Be up-to-date with the technical challenges facing epigenetic research
Evaluate the developments and impact on epigenetics of the latest generation
sequencing technology
Review the companies and projects that are targeting all three epigenetic mechanisms
Easily assess the use of epigenetics in the development of clinical diagnostics
Review the players, alliances and acquisitions in this fast growing area.
Who' s developing what in key areas and what approaches are they taking?
Assess the future development of epigenetic research with an evaluation of
potential applications in disease areas other than cancer
Consider the scope and range of epigenetic research in 5 years time
More Information...
Expert opinions from...
Professor Stephan Beck University College London Cancer Institute
Dr Chris Adams
Senior R&D Manager/ Epigenetics, Life Technologies
Dr Bernd Hentsch
Chief Development Officer,4SC AG
Dr David Simmons (CSO) & Dr Gitte Neubauer
(VP Research Operations), Cellzome
Dr Robert Gould
CEO, Epizyme Inc.
Martin Bonde
CEO, EpiTherapeutics
Dr Andreas Bader
Associate Director of Research, Mirna Therapeutics, Inc.
Table of Contents
The Business Implications
Chapter 1 - Epigenetics Defined
- Epigenetics de fined
- Epigenetic mechanisms
- DNA methylation
- Figure 1: Schematic showing the epigenetic mechanisms of DNA methylation and histone modification
- Chromatin remodelling and histone modifications
- Figure 2: Examples of covalent histone post-translational modifications
- Non-coding RNA
- Figure 3: miRNA processing pathway
- Unravelling the power of epigenetics
- EXPERT COMMENTARY: Professor Stephan Beck, University College London
Cancer Institute
- Consortia for the study of epigenomics
- Which epigenomes and what to study?
- Applications of epigenomic data
- New opportunities for biomarker discovery and drug targeting
- Conclusion and report outline
Chapter 2 - Technical Challenges in Epigenetic R&D
- Executive Summary
- Technical challenges in epigenetic R&D
- TECHNICAL CHALLENGES IN EPIGENETIC R&D
- EXPERT COMMENTARY: Dr Chris Adams, Senior R&D Manager/Epigenetics, Life
Technologies 15
- Next generation sequencing
- Table 1: Platforms for next generation sequencing
- Table 2: Third generation sequencing platforms
- DNA methylation
- Table 3: Methods for studying DNA methylation and their limitations
- Table 4: Suppliers of research tools for the study of DNA methylation
- Chromatin structure and histone modifications
- Figure 4: Schematic of a chromatin immunoprecipitation experiment
- Table 5: Suppliers of research tools for the study of histone and chromatin modifications
- microRNA
- Table 6: Suppliers of research tools for the study of miRNA
- Conclusion
Chapter 3 - Epigenetics in Drug Discovery & Development
- Executive Summary
- Epigenetics in drug discovery & development
- EPIGENETICS IN DRUG DISCOVERY & DEVELOPMENT
- Introduction
- Figure 5: Proteins involved in the modification of histones
- Figure 6: Number of drugs targeting epigenetic mechanisms by mechanism and stage of development
- Epigenetics in cancer
- Epigenetic drug targets in cancer: DNA methyltransferases
- Table 7: Approved drugs targeting DNMTs
- Epigenetic drug targets in cancer: HDAC inhibitors
- Non-selective HDAC inhibitors
- Table 8: Pan-HDAC inhibitors in clinical development
- EXPERT COMMENTARY: Dr Bernd Hentsch, Chief Development Officer, 4SC AG
- Selective HDAC inhibitors
- Table 9: Selective HDAC inhibitors
- EXPERT COMMENTARY: Dr David Simmons (CSO) & Dr Gitte Neubauer (VP
Research Operations), Cellzome 31
- Beyond DNMT and HDAC inhibition: New targets
- Table 10: Companies developing drugs for novel epigenetic targets
- EXPERT COMMENTARY: Dr Robert Gould, CEO, Epizyme Inc
- EXPERT COMMENTARY: Martin Bonde, CEO, EpiTherapeutics
- Cancer the first frontier, where next?
- Table 11: Companies developing therapeutics for epigenetic mechanisms in diseases other than cancer
- Non-coding RNAs
- Table 12: Companies developing therapeutic strategies related to miRNAs
- Table 13: Therapeutic areas for miRNA-based therapeutic discovery
- EXPERT COMMENTARY: Dr. Andreas G. Bader, Associate Director of
Research, Mirna Therapeutics, Inc.37
- The future
Chapter 4 - Epigenetics in Clinical Diagnostics
- Executive Summary
- Epigenetics in clinical diagnostics
- EPIGENETICS IN CLINICAL DIAGNOSTICS
- Introduction
- DNA methylation patterns
- Table 14: Companies developing diagnostics to detect aberrant DNA methylation patterns
- Epigenomics AG
- Figure 7: Epigenomics' development programme
- OncoMethylome Sciences
- Figure 8: OncoMethylome Sciences' development programme
- Orion Genomics
- Figure 9: Orion Genomics' product development pipeline
- Histone modifications
- miRNAs
- Rosetta Genomics
- Table 15: Approved and developmental diagnostic products from Rosetta Genomics
- Asuragen Diagnostics
- Exiqon A/S
- Table 16: Exiqon' s miRNA-based diagnostic pipeline
- Biomarkers and personalised medicine
- Table 17: Diagnostic/pharma partnerships for epigenetic biomarker discovery
- Outlook
Chapter 5 - Players, Alliances & Acquisitions
- Executive Summary
- Players, alliances & acquisitions
- PLAYERS, ALLIANCE S & ACQUISITIONS
- Company activities at a glance - Therapeutics
- Table 18: Areas of focus for companies developing drugs for epigenetic targets
- 4SC AG, Planegg-Martinsried, Germany
- Acetylon Pharmaceuticals Inc, Boston, MA
- Celgene Corporation, Summit, NJ
- Celleron Therapeutics, Oxon, UK
- Cellzome, Cambridge, UK, and Heidelberg, Germany
- Curis Inc, Cambridge MA
- Chroma Therapeutics Ltd, Oxon, UK
- Constellation Pharmaceuticals, Cambridge, MA
- EnVivo Pharmaceuticals, Watertown, MA
- EpiTherapeutics Aps, Copenhagen, Denmark
- Epizyme, Cambridge, MA
- MethylGene, Inc. Montreal, Quebec
- Mirna Therapeutics, Austin, TX
- miRagen Therapeutics, Boulder, CO
- Pharmacyclics, Sunnyvale, CA
- Progen Pharmaceuticals, Brisbane, Australia
- Regulus Therapeutics, Torrey Pines, CA
- Repligen Corporation, Waltham, MA
- Santaris Pharma A/S, Denmark
- SuperGen, Dublin, CA
- Syndax Pharmaceuticals, Waltham, MA
- TopoTarget, Copenhagen, Denmark
- Alliances with market leaders - Therapeutics
- Table 19: Alliances, acquisitions and mergers in the field of epigenetics since 2007
- Table 20: Areas of focus for companies developing diagnostic tests based on epigenetics
- Asuragen Inc, Austin, TX
- Epigenomics AG, Berlin, Germany
- Exiqon, Copenhagen, Denmark
- OncoMethylome Sciences, Durham, NC
- Orion Genomics, Saint Louis, MO
- Rosetta Genomics, Rehovot, Israel
- Alliances with market leaders - Diagnostics
- Conclusion
Chapter 6 - Outlook & Future of Epigenetic Research
- OUTLOOK & FUTURE OF EPIGENETIC RESEARCH
- Epigenetics research now
- Figure 10: Progress in epigenetics related therapeutics and diagnostics over the next 5 years
- Therapeutic launches and new indications over the next 5 years
- Table 21: Revenues generated by Vidaza, Dacogen and Zolinza in 2009
- New combinations and a changing therapeutic paradigm in cancer
- Table 22: Examples of clinical trials of combinations of DNMTi, HDACi and chemotherapy
- Table 23: Examples of clinical trials of drug combinations including panobinostat
- New diagnostic products
- Table 24: New diagnostic products identifying epigenetic biomarkers that will be launched to the market over the next few years69
- Next generation sequencing
- Epigenetics research in 5 to 10 years time
- Figure 11: Progress in epigenetics related therapeutics and diagnostics over the next 5 to 10 years
- Therapeutic launches
- Therapeutics and companion diagnostics for novel epigenetic targets
- Epigenetics research more than 10 years from now
- Figure 12: Progress in epigenetics-related therapeutics and diagnostics 10 years +
- Conclusions
GLOSSARY
BIOGRAPHY OF THE AUTHOR
REFERENCES
ENDNOTES
|
 |
